Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Neoplastic Meningitis
NCT00924820Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2009
- Primary completion
- Sep 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in neoplastic meningitis (NM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Cerebrospinal Fluid Response Rate at 54 weeks and Time to Neurological Progression at 6 weeks. Started Jun 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
neoplastic meningitis (NM)
Beyond the preview
Go deeper on NCT00924820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00924820.